Detalles de la búsqueda
1.
Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma.
Cancers (Basel)
; 15(20)2023 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37894278
2.
Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.
Breast Cancer Res
; 14(1): R2, 2012 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-22225778
3.
Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
Breast Cancer Res Treat
; 135(2): 433-44, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22825030
4.
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
BMC Cancer
; 11: 468, 2011 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-22039910
5.
Editor's Note: Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells.
Clin Cancer Res
; 30(9): 1994, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38690597
6.
Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.
BMC Cancer
; 8: 318, 2008 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-18980695
7.
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Mol Cancer Ther
; 11(4): 973-83, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22367781
8.
Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Clin Cancer Res
; 18(22): 6227-38, 2012 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22932665
9.
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Clin Cancer Res
; 17(23): 7347-58, 2011 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21976548
10.
Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms.
Neoplasia
; 12(5): 425-33, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20454514
11.
Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting.
Cancer Ther
; 7(A): 254-267, 2009 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-20651940
12.
Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.
Pharmacogenet Genomics
; 19(6): 477-88, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19440163
13.
Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells.
Epigenetics
; 3(5): 270-80, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19001875
14.
Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells.
Anticancer Drugs
; 18(5): 499-523, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17414620
15.
Changes in expression of cell wall turnover genes accompany inhibition of chromosome segregation by bovine protein kinase C alpha expression in Saccharomyces cerevisiae.
Cell Biol Int
; 31(10): 1160-72, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17512223
16.
cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Breast Cancer Res Treat
; 96(1): 17-39, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16322897
17.
The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data.
Anal Biochem
; 345(2): 237-49, 2005 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16139235
18.
Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization.
Breast Cancer Res Treat
; 82(2): 125-41, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14692656
19.
Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure.
Breast Cancer Res Treat
; 85(1): 31-51, 2004 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15039596
Resultados
1 -
19
de 19
1
Próxima >
>>